Behaviour change interventions to promote prescribing of generic drugs: A rapid evidence synthesis and systematic review

BMJ Open

Volumn 4, Issue 5, 2014, Pages

  Moe Byrne, Thirimon ^a   Chambers, Duncan ^a   Harden, Melissa ^a   McDaid, Catriona ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; GENERIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ACTIVE FEEDBACK; BEHAVIOR CHANGE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DECISION MAKING; ELECTRONIC PRESCRIBING; FINANCE; FINANCIAL INCENTIVE; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; INTERDISCIPLINARY CONTINUING EDUCATION; MEDICAL AUDIT; MEDICAL EDUCATION; NATIONAL HEALTH SERVICE; NETWORKING INTERVENTION; PASSIVE FEEDBACK; PHARMACIST; PHYSICIAN; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STRUCTURED FEEDBACK; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES; BEHAVIOR; GREAT BRITAIN; STANDARDS; STATISTICS AND NUMERICAL DATA;

BEHAVIOR; DRUG PRESCRIPTIONS; DRUGS, GENERIC; GREAT BRITAIN; HUMANS; PRACTICE PATTERNS, PHYSICIANS';

EID: 84901497250     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004623     Document Type: Review

References (41)

1. The European Parliament and the Council of the European Union. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union 2004;136:34-57.
2. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. J Generic Med 2006;3:257-68. (Pubitemid 46218086)
3. Prescribing and Primary Care Services Health and Social Care Information Centre. Prescriptions dispensed in the community: England 2002-12. Health and Social Care Information Centre, 2013.
4. Department of Health. The proposals to implement 'Generic Substitution' in primary care, further to the Pharmaceutical Price Regulation Scheme (PPRS) 2009: response to the consultation. London: Department of Health; 2010.
5. National Audit Office. Prescribing costs in primary care. London: The Stationery Office, 2007.
6. Sturm H, Austvoll-Dahlgren A, Aaserud M, et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst Rev 2007;(3):CD006731.
7. Kaplan WA, Ritz LS, Vitello M, et al. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy 2012;106:211-24.
8. Carroll NV. Do community pharmacists influence prescribing? J Am Pharm Assoc 2003;43:612-21.
9. McKibbon KA, Lokker C, Handler SM, et al. Enabling medication management through health information technology. Rockville, MD: Agency for Healthcare Research and Quality, 2011.
10. Mitchell E, Sullivan F. A descriptive feast but an evaluative famine: systematic review of published articles on primary care computing during 1980-97. BMJ 2001;322:279-82. (Pubitemid 32178556)
11. Figueiras A, Sastre I, Gestal-Otero JJ. Effectiveness of educational interventions on the improvement of drug prescription in primary care: a critical literature review. J Eval Clin Pract 2001;7:223-41. (Pubitemid 32489014)
12. Green CJ, Maclure M, Fortin PM, et al. Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database Syst Rev 2010;(8):CD008654.
13. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012;(6):CD000259.
14. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care 2005;11:730-40. (Pubitemid 41608213)
15. Newcastle and North Tyneside Health Authority. Precept: Prescribing cost effectiveness programme toolkit. Newcastle: Newcastle and North Tyneside Health Authority; 1999.
16. Meyer JC, Summers RS, Moller H. Randomized, controlled trial of prescribing training in a South African province. Med Educ 2001;35:833-40. (Pubitemid 34212144)
17. Braybrook S,Walker R. Influencing NSAID prescribing in primary care using different feedback strategies. PharmWorld Sci 2000;22:39-46. (Pubitemid 30306119)
18. Wensing M, Broge B, Riens B, et al. Quality circles to improve prescribing of primary care physicians. Three comparative studies. Pharmacoepidemiol Drug Saf 2009;18:763-9.
19. Mastura I, Teng CL. The effect of "group detailing " on drug prescribing in primary care. Med J Malaysia 2008;63:315-18.
20. Fischer MA, Vogeli C, Stedman M, et al. Effect of electronic prescribing with formulary decision support on medication use and cost. Arch Intern Med 2008;168:2433-9.
21. Geoghegan M, Pilling M, Holden J, et al. A controlled evaluation of the effect of community pharmacists on general practitioner prescribing. Pharm J 1998;261:864-6. (Pubitemid 28550155)
22. Leach RH, Wakeman A. An evaluation of the effectiveness of community pharmacists working with GPs to increase the cost-effectiveness of prescribing. Pharm J 1999;263:206-9. (Pubitemid 29396520)
23. Onion CWR, Dutton C. Improving prescribing in primary care: goals, emotions, and personal agency beliefs. Clin Manag 1998;7:117-20.
24. Walker J, Mathers N. The impact of a general practice group intervention on prescribing costs and patterns. Br J Gen Pract 2002;52:181-6. (Pubitemid 34192907)
25. Wensing M, Broge B, Kaufmann-Kolle P, et al. Quality circles to improve prescribing patterns in primary medical care: what is their actual impact? J Eval Clin Pract 2004;10:457-66. (Pubitemid 39093752)
26. Niquille A, Ruggli M, Buchmann M, et al. The nine-year sustained cost-containment impact of Swiss pilot physicians-pharmacists quality circles. Ann Pharmacother 2010;44:650-7.
27. Stenner SP, Chen Q, Johnson KB. Impact of generic substitution decision support on electronic prescribing behavior. JAMA 2010;17:681-8.
28. Lopez-Picazo Ferrer JJ, Sanz Moreno JA, Bernal Montanes JM, et al. Evaluating, improving and monitoring generic drug prescription. Aten Primaria 2002;29:397-406.
29. Department of Health. Strategies to achieve cost-effective prescribing: guidance for Primary Care Trusts and Clinical Commissioning Groups. Leeds: Department of Health, 2010.
30. Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol 2010;70:335-41.
31. Ferner RE, Lenney W, Marriott JF. Controversy over generic substitution. BMJ 2010;340:c2548.
32. Department of Health. Cost-effective prescribing: Better Care Better Value (BCBV) indicator on statins. London: Department of Health, 2011.
33. Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev PharmacoEconomics Outcomes Res 2013;13:469-82.
34. Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev PharmacoEconomics Outcomes Res 2011;11:343-9.
35. Andersson KA, Petzold MG, Allebeck P, et al. Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years. BMC Health Serv Res 2008;8:50.
36. Dylst P, Vulto A, Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev PharmacoEconomics Outcomes Res 2011;11:729-37.
37. Bennie M, Bishop I, Godman B, et al. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: international implications. Int J Clin Pract 2013;67:170-80.
38. O'Brien MA, Oxman AD, Davis DA, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007;(4):CD000409.
39. Sakshaug S, Furu K, Karlstad O, et al. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81. (Pubitemid 47404299)
40. Martikainen JE, Saastamoinen LK, Korhonen MJ, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care 2010;48:761-6.
41. Bucsics A, Godman B, Burkhardt T, et al. Influence of lifting prescribing restrictions for losartan on subsequent losartan utilization patterns in Austria: implications for other countries. Expert Rev PharmacoEconomics Outcomes Res 2012;12:809-19.